IPP Bureau

Pharmaceuticals & Medical Devices Bureau of India partnered with cooperative sector to open Jan Aushadhi Kendras through PACS
Pharmaceuticals & Medical Devices Bureau of India partnered with cooperative sector to open Jan Aushadhi Kendras through PACS

By IPP Bureau - December 16, 2024

Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS

Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care
Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care

By IPP Bureau - December 16, 2024

Harnessing advanced data analysis for early detection, prevention and better outcomes

Gilead Sciences appoints Dietmar Berger as Chief Medical Officer
Gilead Sciences appoints Dietmar Berger as Chief Medical Officer

By IPP Bureau - December 14, 2024

Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines

Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy

By IPP Bureau - December 14, 2024

Final decision from the European Commission is anticipated within the coming months

Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio

By IPP Bureau - December 14, 2024

The trademark rights for these brands will be transferred to Lupin by March next year.

CuraTeQ Biologics receives positive opinion for biosimilar Zefylti
CuraTeQ Biologics receives positive opinion for biosimilar Zefylti

By IPP Bureau - December 14, 2024

Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells

Pfizer announces Phase 3 PATINA study in patients with HR+, HER2+ metastatic breast cancer
Pfizer announces Phase 3 PATINA study in patients with HR+, HER2+ metastatic breast cancer

By IPP Bureau - December 13, 2024

IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy

Lonza outlines strategy, new organizational structure and guidance
Lonza outlines strategy, new organizational structure and guidance

By IPP Bureau - December 12, 2024

The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities

Brenntag Specialties engages Esprit Care for its Southeast Asia nutraceutical market expansion
Brenntag Specialties engages Esprit Care for its Southeast Asia nutraceutical market expansion

By IPP Bureau - December 12, 2024

Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain

Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial
Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial

By IPP Bureau - December 12, 2024

First and only PARP inhibitor to improve overall survival in early breast cancer

AbbVie completes acquisition of Aliada Therapeutics
AbbVie completes acquisition of Aliada Therapeutics

By IPP Bureau - December 12, 2024

Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease

Gland Pharma receives approval for phytonadione injection emulsion
Gland Pharma receives approval for phytonadione injection emulsion

By IPP Bureau - December 12, 2024

This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.

Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
Biocon Biologics recognized as Asia IP Elite for 2024 by IAM

By IPP Bureau - December 12, 2024

Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list

Briefs: Alembic Pharmaceuticals and Veerhealth Care
Briefs: Alembic Pharmaceuticals and Veerhealth Care

By IPP Bureau - December 12, 2024

The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market

Genpharmasec enters into supper stockist agreement with Amneal Healthcare
Genpharmasec enters into supper stockist agreement with Amneal Healthcare

By IPP Bureau - December 11, 2024

Latest Stories

Interviews

Packaging